← Beijing Sun Novo Pharmaceutical Research overview

Beijing Sun Novo Pharmaceutical Research vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Beijing Sun Novo Pharmaceutical Research Co Ltd (688621.CG)

Q3 2026
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

August 2026
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Latest
▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

  • H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.

    The loss is the core financial result that directly pressures the share price.

  • STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.

    Clinical approval is a concrete pipeline win that can lift investor sentiment.

  • STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.

    Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.

  • Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.

    The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Avantor Inc (AVTR)

Q3 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

August 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.